Table 1 Univariable analysis of overall-free and relapse-free survival, relapse incidence and non-relapse mortality.
Variables | N | 5-yr OS (95% CI) | p-value | 5-yr RFS (95% CI) | p-value | 5-yr CIR (95% CI) | p-value | 5-yr NRM (95% CI) | p-value |
|---|---|---|---|---|---|---|---|---|---|
Total cohort | 39 | 49 (35–68) | 29 (17–48) | 42 (26–58) | 29 (14–44) | ||||
Patient age at HCT | |||||||||
<60 years | 26 | 46 (29–72) | 0.85 | 25 (12–50) | 0.34 | 51 (31–72) | 0.10 | 24 (6–42) | 0.58 |
≥60 years | 13 | 54 (33–89) | 38 (19–76) | 23 (0–48) | 38 (11–66) | ||||
HCT-CI, score | |||||||||
<3 | 28 | 54 (38–77) | 0.11 | 31 (17–54) | 0.47 | 44 (24–63) | 0.94 | 26 (9–43) | 0.28 |
≥3 | 11 | 36 (17–79) | 27 (10–72) | 36 (6–67) | 36 (5–68) | ||||
Detection of deletion(17p)/TP53mut | |||||||||
During Course CLL | 14 | 38 (18–79) | 0.84 | 18 (5–60) | 0.32 | 52 (22–81) | 0.26 | 30 (3–58) | 0.84 |
At diagnosis | 25 | 54 (38–78) | 36 (21–61) | 36 (17–55) | 28 (10–46) | ||||
Disease stage | |||||||||
First remission | 13 | 69 (48–99) | 0.12 | 54 (33–89) | 0.04 | 23 (0–47) | 0.050 | 23 (0–47) | 0.40 |
Advanced stage | 26 | 39 (23–64) | 18 (8–42) | 51 (30–71) | 31 (12–50) | ||||
Remission status before conditioning | |||||||||
Complete remission | 8 | 47 (21–100) | 0.92 | 33 (12–96) | 0.51 | 42 (0–84) | 0.56 | 25 (0–57) | 0.76 |
Partial remission | 31 | 49 (34–71) | 28 (15-50) | 42 (24–60) | 30 (13–48) | ||||
Alemtuzumab last line prior to HCT | |||||||||
No | 10 | 34 (14–85) | 0.11 | 20 (6–69) | 0.02 | 40 (7–73) | 0.17 | 40 (6–74) | 0.06 |
Yes | 29 | 53 (37–76) | 32 (18–56) | 43 (23–62) | 26 (8–44) | ||||
Donor type | |||||||||
HLA-identical sibling | 11 | 36 (17–79) | 0.29 | 27 (10–72) | 0.46 | 45 (13–78) | 0.50 | 27 (0–56) | 0.73 |
Alternative donor | 28 | 53 (37–77) | 30 (16–54) | 40 (21–59) | 30 (12–48) | ||||
